Comparison of the infectious and immunological safety of a low-bacterial and modified diet in allogeneic hematopoietic stem cell transplantation in adults

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Malnutrition is an aggravating factor in hematopoietic stem cell transplantation (HSCT). Due to the need for the intestinal microbiome protection, which is a key element in homeostasis and is under complex negative effects, a theory aimed at liberalizing dietary restrictions is being developed, which creates the basis for improving the patient’s self-feeding and leads to a number of positive outcomes.

Aim. To evaluate the infectious and immunological safety of a modified diet in HSCT.

Materials and methods. From 2022 to 2023 at the Raisa Gorbacheva Memorial Research Institute 406 allogeneic HSCT recipients over 18 years old, who followed a low-bacterial (LBD) (n = 177) or modified diet (MD) (n = 229) were enrolled to the randomized trial. The concept of LBD included generally accepted anti-infective restrictions in HSCT, the absence of gluten, lactose, and yeast-containing products. Under MD, only the principles of anti-infective measures were maintained in the preparation, storage, transportation and dishes consumption, and the prohibition of a sharply limited list of foods that are difficult to digest and capable of mechanically injuring the oropharynx and gastrointestinal tract mucous membrane.

Results. The patient groups were homogeneous in diagnosis, graft source, HLA-compatibility between the recipient and the donor, conditioning regimen intensity and graft-versus-host disease prophylaxis, except for the age: MD group – 42.3 years, LBD group – 38.4 years; p = 0.009. The one-year overall survival was similar in both groups: 72 % for MD and 75 % for LBD; p = 0.6. Relapse-free one-year mortality was comparable between the groups: 8.7 % for MD versus 9.1 % for LBD; p = 0.9. Graft engraftment at day 30 did not differ: 83 and 92 %, respectively; p = 0.2. The incidence of graft-versus-host disease grade 3–4 was 3.4 % in the MD group and 6.8 % in the LBD group, respectively; p = 0.14. The incidence of bloodstream infections at day 30 was lower in the MD group (14.4 %) compared with the LBD group (45.2 %), respectively; p <0.001.

Conclusion. Using the example of the presented patient cohort who underwent allogeneic HSCT, the use of MD has potential advantages over LBD in the form of a tendency to reduce bloodstream infections and the severe graft-versus-host disease incidence. Further studies with a large number of participants are needed to confirm these findings.

About the authors

M. A. Kucher

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: doctorkucher@yandex.ru
ORCID iD: 0000-0001-6114-3214

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

N. P. Volkov

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru
ORCID iD: 0000-0001-6161-1444

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

Y. A. Tarakanova

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru
ORCID iD: 0009-0003-0961-7103

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

T. A. Gogoleva

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

N. G. Saltykova

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

M. M. Kanunnikov

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

Y. Y. Vlasova

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru
ORCID iD: 0000-0002-7762-0107

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

A. D. Kulagin

I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: doctorkucher@yandex.ru
ORCID iD: 0000-0002-9589-4136

Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation

Russian Federation, 6–8 L’va Tolstogo St., Saint Petersburg 197022

References

  1. Afanasiev B.V., Zubarovskaya L.S., Moiseev I.S. Allogeneic hematopoietic stem cell transplantation in children: now, problems and prospects. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2015;2(2):28–42. (In Russ.). doi: 10.17650/2311-1267-2015-2-2-28-42
  2. Lipkin A.C., Lenssen P., Dickson B.J. Nutrition issues in hematopoietic stem cell transplantation: state of the art. Nutr Clin Pract 2005;20(4):423–39. doi: 10.1177/0115426505020004423
  3. Casirati A., Salcedo I., Cereda E. et al. The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT. Bone Marrow Transplant 2023;58(9):965–72. doi: 10.1038/s41409-023-02018-z
  4. Arends J., Bachmann P., Baracos V. et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36(1):11–48. doi: 10.1016/j.clnu.2016.07.015
  5. Baumgartner A., Bargetzi A., Zueger N. et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation – a systematic review. Bone Marrow Transplant 2017;52(4):506–13. doi: 10.1038/bmt.2016.310
  6. Baumgartner A., Schuetz P. Nutritional support. In: The EBMT Handbook. Hematopoietic stem cell transplantation and cellular therapies. Eds.: E. Carreras, C. Dufour, M. Mohty, N. Kröger. 2019. Pp. 171–176. doi: 10.1007/978-3-030-02278-5
  7. Preisler H.D., Goldstein I.M., Henderson E.S. Gastrointestinal “sterilization” in the treatment of patients with acute leukemia. Cancer 1970;26(5):1076–81. doi: 10.1002/1097-0142(197011)26:5<1076::aid-cncr2820260516>3.0.co;2-d
  8. Pizzo P.A., Purvis D.S., Waters C. Microbiological evaluation of food items. For patients undergoing gastrointestinal decontamination and protected isolation. J Am Diet Assoc 1982; 81(3):272–9.
  9. Jubelirer S.J. The benefit of the neutropenic diet: fact or fiction? Oncologist 2011;16(5):704–7. doi: 10.1634/theoncologist.2011-0001
  10. Lassiter M., Schneider S.M. A pilot study comparing the neutropenic diet to a non-neutropenic diet in the allogeneic hematopoietic stem cell transplantation population. Clin J Oncol Nurs 2015;19(3):273–8. doi: 10.1188/15.CJON.19-03AP
  11. Van Dalen E.C., Mank A., Leclercq E. et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. Cochrane Database Syst Rev 2016;24(4):CD006247. doi: 10.1002/14651858.CD006247.pub3
  12. Taggart C., Neumann N., Alonso P.B. et al. Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2019;25(7):1382–6. doi: 10.1016/j.bbmt.2019.03.017
  13. Baumgartner A., Hoskin K., Schuetz P. Optimization of nutrition during allogeneic hematologic stem cell transplantation. Curr Opin Clin Nutr Metab Care 2018;21(3):152–8. doi: 10.1097/MCO.0000000000000461
  14. Staffas A., Burgos da Silva M., van den Brink M.R. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 2017;129(8):927–33. doi: 10.1182/blood-2016-09-691394
  15. Peric Z., Botti S., Stringer J. et al. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 2018;53(8):1030–7. doi: 10.1038/s41409-018-0137-1
  16. Trifilio S., Helenowski I., Giel M. et al. Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation. Biol Blood Marrow Transplant 2012;18(9):1385–90. doi: 10.1016/j.bbmt.2012.02.015
  17. Skobelev D., Skorobogatova E., Kirghizov K. Breastfeeding is not contraindicated in patients undergoing HSCT. SIOP 10th Asia Congress. Abstract book. 2016. P. 120.
  18. Ifversen M., Meisel R., Sedlacek P. et al. Supportive care during pediatric hematopoietic stem cell transplantation: prevention of infections. A report from workshops on supportive care of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Front Pediatr 2021;9:705179. doi: 10.3389/fped.2021.705179
  19. Ministry of Health of the Russian Federation. Order No. 1008n of September 23, 2020, “On Approving the Procedure for Providing Patients with Therapeutic Nutrition”. Available at: https://publication.pravo.gov.ru/Document/View/0001202010010037 (accessed June 27, 2025) (In Russ.)
  20. Bozzetti F., Arends J., Lundholm K. et al. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr 2009;28(4):445–54. doi: 10.1016/j.clnu.2009.04.011
  21. Snegovoy A.V., Larionova V.B., Kononenko I.B. et al. Prevention of nausea and vomiting in oncology. Klinicheskaya onkogematologiya = Clinical Oncohematology 2016;9(1):75–83. (In Russ.). doi: 10.21320/2500-2139-2016-9-1-75-83
  22. Moody K. Neutropenic dietary restrictions for hematopoietic stem cell patients: time for a change. Biol Blood Marrow Transplant 2019;25(7):e223–5. doi: 10.1016/j.bbmt.2019.05.011
  23. Seattle Cancer Care Alliance. Diet guidelines for immunosuppressed patients. 2011. Available at: https://healthonline.washington.edu/sites/default/files/record_pdfs/Diet-Guidelines-Immunosuppressed-Patients-SCCA.pdf (accessed 27.06.2025)

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Supplement 1 Low-microbial diet as a variant of the standard high-protein diet (based on the low-microbial diet proposed by K. Moody [22])
Download (332KB)
3. Supplement 2 Modified diet as a variant of the standard high-protein diet (based on the modified diet proposed by C. Taggart et al.; Seattle Cancer Care Alliance [12, 23])
Download (301KB)

Copyright (c) 2026 ABV-press

License URL: https://oncohematology.abvpress.ru/ongm/about/editorialPolicies

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.

The website of the journal Oncohematology contains materials intended exclusively for healthcare professionals.

By closing this message, you confirm* that you are a licensed healthcare professional or a student of a medical educational institution.

This one-time confirmation is valid for the next 30 days.